Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Cagrilintide

AM-833, Long-acting amylin analogue

Quick Stats
Studies 57
Trials 38
Recruiting PHASE1 INTERVENTIONAL NCT07184086

A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

View on ClinicalTrials.gov Updated Dec 15, 2025

Brief Summary

In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors but has previously been tested in humans. The study is split into 2 parts. In the first part of the study, participants will either get CagriSema or a weight loss diet (calorie reduced). In the second part of the study,all participants will get CagriSema. Which treatment participants get in the first part of the study is decided by chance. Like all medicines, the study medicine may have side effects. The study will last for about 1.5 years.

Interventions

Name: CagriSema (Cagrilintide B + semaglutide I)
Type: DRUG
Description: Cagrilintide and semaglutide will be administered subcutaneously.
Name: Low Energy Diet
Type: BEHAVIORAL
Description: Participants will receive dietary intervention as per diet intervention manual.

Primary Outcomes

Measure: Change in sleeping metabolic rate (SMR)
TimeFrame: Baseline (Week 0) to Week 20
Description: Measured as kilojoules (kJ) per day.

Trial Information

NCT ID

NCT07184086

Status

Recruiting

Study Type

INTERVENTIONAL

Phases

PHASE1

Sponsor

Novo Nordisk A/S

Last Updated

December 15, 2025